US Stock MarketDetailed Quotes

GKOS Glaukos

Watchlist
  • 153.200
  • +6.820+4.66%
Close Feb 14 16:00 ET
  • 152.610
  • -0.590-0.39%
Pre 05:20 ET
8.45BMarket Cap-52.29P/E (TTM)

About Glaukos Company

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.

Company Profile

SymbolGKOS
Company NameGlaukos
Listing DateJun 25, 2015
Issue Price18.00
Founded1998
CEOMr. Thomas W. Burns
MarketNYSE
Employees907
Fiscal Year Ends12-31
AddressOne Glaukos Way
CityAliso Viejo
ProvinceCalifornia
CountryUnited States of America
Zip Code92656
Phone1-949-367-9600

Company Executives

  • Name
  • Position
  • Salary
  • Thomas W. Burns
  • Chairman of the Board and Chief Executive Officer
  • 8.65M
  • Dr. Tomas Navratil
  • Chief Development Officer
  • 2.57M
  • Joseph E. Gilliam
  • President and Chief Operating Officer
  • 4.18M
  • Alex R. Thurman
  • Senior Vice President, Chief Financial Officer and Principal Accounting Officer
  • 2.36M
  • Dr. Gilbert H. Kliman, M.D.
  • Independent Director
  • 259.00K
  • Marc A. Stapley
  • Independent Director
  • 273.39K
  • David F. Hoffmeister
  • Independent Director
  • 262.13K
  • Dr. Leana S. Wen, M. Sc.,M.D.
  • Independent Director
  • 259.00K
  • Aimee S. Weisner
  • Independent Director
  • 259.00K
  • Mark J. Foley
  • Lead Independent Director
  • 319.38K
  • Denice M. Torres, J.D.,M.B.A.
  • Independent Director
  • 259.00K

Trending Stocks

Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio? Show More